PharmaShots | Incisive News in 3 Shots

Subscribe Now

coherus

Coherus to Highlight Final P-II Study Data of Casdozokitug Regimen to Treat Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus to Highlight Final P-II Study Data of Casdozokitug Regimen to Treat Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

January 23, 2025

Coherus Reports the Divestment of Yusimry (Biosimilar, Humira) to Hong Kong King-Friend Industry

Coherus Reports the Divestment of Yusimry (Biosimilar, Humira) to Hong Kong King-Friend Industry

June 28, 2024

Coherus Highlights Results from the P-II Study of Casdozokitug for Advanced or Metastatic Hepatocellular Carcinoma (uHCC)

Coherus Highlights Results from the P-II Study of Casdozokitug for Advanced or Metastatic Hepatocellular Carcinoma (uHCC)

January 19, 2024

Coherus and Junshi Biosciences Received the US FDA’s Approval for Loqtorzi (toripalimab-tpzi) to Treat Nasopharyngeal Carcinoma (NPC)

Coherus and Junshi Biosciences Received the US FDA’s Approval for Loqtorzi (toripalimab-tpzi) to Treat Nasopharyngeal Carcinoma (N...

October 31, 2023

Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount

Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount

July 3, 2023

Coherus Receives the US FDA’s Approval of Udenyca (biosimilar, pegfilgrastim) for Febrile Neutropenia

Coherus Receives the US FDA’s Approval of Udenyca (biosimilar, pegfilgrastim) for Febrile Neutropenia

March 7, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us